Annuncio pubblicitario
Italia markets closed

  • FTSE MIB

    33.645,42
    -90,98 (-0,27%)
     

  • Dow Jones

    38.657,06
    +431,40 (+1,13%)
     

  • Nasdaq

    16.142,47
    +301,51 (+1,90%)
     

  • Nikkei 225

    38.236,07
    -37,98 (-0,10%)
     

  • Petrolio

    78,62
    -0,33 (-0,42%)
     

  • Bitcoin EUR

    57.118,78
    +2.068,65 (+3,76%)
     

  • CMC Crypto 200

    1.323,91
    +46,94 (+3,68%)
     

  • Oro

    2.302,20
    -7,40 (-0,32%)
     

  • EUR/USD

    1,0781
    +0,0053 (+0,50%)
     

  • S&P 500

    5.120,07
    +55,87 (+1,10%)
     

  • HANG SENG

    18.475,92
    +268,79 (+1,48%)
     

  • Euro Stoxx 50

    4.918,81
    +28,20 (+0,58%)
     

  • EUR/GBP

    0,8582
    +0,0028 (+0,32%)
     

  • EUR/CHF

    0,9743
    -0,0017 (-0,17%)
     

  • EUR/CAD

    1,4739
    +0,0077 (+0,53%)
     

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

Atossa Therapeutics, Inc.
·1 minuto per la lettura
Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc.

SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces that the Company will take part in the upcoming Cantor Fitzgerald Global Healthcare Conference 2023.

Details of the company's participation are as follows:

  • Cantor Fitzgerald Global Healthcare Conference 2023

  • Format: Fireside Chat with Chief Executive Officer Steven Quay, M.D., Ph.D.

  • Date and Time: Thursday, September 28th at 9:10 A.M. ET

  • Location: New York, NY

ANNUNCIO PUBBLICITARIO

Interested parties may access the live webcast of the fireside chat by visiting the Investors section of the Atossa website at https://investors.atossatherapeutics.com. The webcast replay will be archived on the Atossa website for 90 days following the conclusion of the event.

About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. For more information, please visit www.atossatherapeutics.com.

Contact:
Eric Van Zanten
VP, Investor and Public Relations
610-529-6219
eric.vanzanten@atossainc.com